Table 1.

Clinical features of all patients

Clinical features	Experiment type
	Immunohistochemistry	Taylor dataset
Prostate cancer (Cases)	97	150
Mean age	70.71 ± 8.00	58.34 ± 7.07
≤ 66	26	125
> 66	71	25
Serum PSA levels (ng/ml)
< 4	-	24
≥ 4	-	123
Gleason score
≤ 6	26	41
7	43	76
≥ 8	28	22
Metastasis	0	28
Adjacent benign tissue (Cases)	81	29

Note: the “-” means that there are lack of relative information of patients in our cohort. All 150 patients in the Taylor dataset were given a follow-up exam ranging from 1 to 175 months (median, 55 months). For the analysis of survival and follow-up, the date of prostatectomy was used as the beginning of the follow-up period. The primary analysis endpoint for the cohort of patients was time to biochemical recurrence. Other analysis endpoint was overall survival. All the patients who died from diseases other than PCa or unexpected events were excluded from the cohort.